Chemotherapy for triple-negative breast cancer occupies an important clinical position in the whole treatment process. Preoperative chemotherapy, i.e. chemotherapy before surgical treatment, also known as neoadjuvant chemotherapy regimen, is mostly used in locally advanced cases. The purpose is to shrink the tumor, improve the chance of successful surgery, as well as detect the sensitivity of the tumor to drugs. Triple-negative breast cancer is not sensitive to endocrine therapy and targeted therapy, and neoadjuvant chemotherapy is the main treatment. In the clinic, the drugs can be anthracycline, such as doxorubicin, Zoerythromycin, combined with paclitaxel program, such as paclitaxel, usually with 4~6 courses of treatment, but also with platinum drugs. Specific should be standardized and individualized treatment under the guidance of professional physicians, the drugs also need to be applied under the guidance of doctors, do not unauthorized use of drugs.